

L Number	Hits	Search Text	DB	Time stamp
1	11466	vanill\$	USPAT; US-PPGPUB; EPO; DERWENT USPAT; US-PPGPUB; EPO; DERWENT USPAT; US-PPGPUB; EPO; DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:30
2	33	vanill\$ and (cannabinoid or CB1)	DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:33
3	6147	vanill\$ and (derivative or analog)	DERWENT USPAT; US-PPGPUB; EPO; DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:33
4	140	(vanill\$ and (derivative or analog)) and N-acyl	DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:35
5	2055	(vanill\$ and (derivative or analog)) and amide	DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:35
6	107	((vanill\$ and (derivative or analog)) and amide) and N-acyl	DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:44
7	520	514/613	DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:44
8	17	514/613 and vanil\$	DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:47
9	1162	514/563	DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:47
10	30	514/563 and vanil\$	DERWENT USPAT; US-PPGPUB; EPO;	2003/05/16 21:48

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1623kxg

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:22:44 ON 16 MAY 2003

```
=> filereg  
FILEREG IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (>).
```

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:22:56 ON 16 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2003 HIGHEST RN 516445-69-5
DICTIONARY FILE UPDATES: 15 MAY 2003 HIGHEST RN 516445-69-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 09787764-3.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 11 sss sam
SAMPLE SEARCH INITIATED 14:23:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 318 TO ITERATE
```

```
100.0% PROCESSED 318 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5291 TO 7429
PROJECTED ANSWERS: 1 TO 80
```

```
L2 1 SEA SSS SAM L1
```

```
=> s 11 sss full
FULL SEARCH INITIATED 14:23:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6605 TO ITERATE
```

```
100.0% PROCESSED 6605 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.01
```

```
L3 11 SEA SSS FUL L1
```

```
=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
                           ENTRY SESSION
FULL ESTIMATED COST          148.55   148.76
```

```
FILE 'CAPLUS' ENTERED AT 14:23:59 ON 16 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 May 2003 VOL 138 ISS 21
FILE LAST UPDATED: 15 May 2003 (20030515/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3 and (tumor or carcinoma or sclerosis or psoriasis or keratosis or asthma or rhinitis or athero? or restenosis)

10 L3
277459 TUMOR
115452 TUMORS
315962 TUMOR
(TUMOR OR TUMORS)
99854 CARCINOMA
23296 CARCINOMAS
157 CARCINOMATA
106398 CARCINOMA
(CARCINOMA OR CARCINOMAS OR CARCINOMATA)
15689 SCLEROSIS
27 SCLEROSES
15707 SCLEROSIS
(SCLEROSIS OR SCLEROSES)
8799 PSORIASIS
1082 KERATOSIS
286 KERATOSES
1278 KERATOSIS
(KERATOSIS OR KERATOSES)
20778 ASTHMA
20 ASTHMAS
20785 ASTHMA
(ASTHMA OR ASTHMAS)
3497 RHINITIS
41546 ATHERO?
4595 RESTENOSIS
L4 1 L3 AND (TUMOR OR CARCINOMA OR SCLEROSIS OR PSORIASIS OR KERATOSIS OR ASTHMA OR RHINITIS OR ATHERO? OR RESTENOSIS)

=> dis 14 ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:472376 CAPLUS
DOCUMENT NUMBER: 119:72376
TITLE: Preparation of phellodendrine analogs as allergy inhibitors
INVENTOR(S): Koda, Akihide; Nishioka, Itsuo; Kawamura, Hideki; Ono, Yutaka; Hosaka, Kunio; Matsuoka, Yoshiyuki; Ogawa, Yoshimitsu; Fujisawa, Shinichi
PATENT ASSIGNEE(S): Tsumura and Co., Japan
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9220645	A1	19921126	WO 1992-JP647	19920520
W: AU, CA, JP, KR, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2103367	AA	19921121	CA 1992-2103367	19920520
EP 613879	A1	19940907	EP 1992-910349	19920520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
AU 9217924	A1	19921230	AU 1992-17924	19920522
AU 658188	B2	19950406		
PRIORITY APPLN. INFO.:			JP 1991-143858	19910520
			JP 1991-143987	19910520
			WO 1992-JP647	19920520

OTHER SOURCE(S): MARPAT 119:72376

GI For diagram(s), see printed CA Issue.


AB Phellodendrine analogs [I; A = (hydroxy- or alkoxy)benzyl, -phenethyl; B = H, alkyl, acyl; ABN = tetrahydroisoquinoline group Q (wherein R3, R4 = H, OH, alkoxy); R1, R2 = H, OH, alkoxy; n = 0-2; m = 0, 1], effective in treating allergy type IV syndromes, such as chronic hepatitis, intractable asthma, nephrotic syndrome, or rheumatism, are prepd. and formulated. A soln. of m-MeOC₆H₄COCl in C₆H₆ was added dropwise to a soln. of m-MeOC₆H₄CH₂NH₂ in C₆H₆ contg. pyridine under cooling and the soln. was stirred at room temp. to give 94.2% amide II, which was formulated into 200-mg tablets contg. 20 mg active ingredient, and which showed 25.1% inhibition of allergy type IV at 3 times 10⁻⁴ mol/kg.

IT 148234-91-7P 148235-12-5P 148235-22-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP. (Preparation); USES (Uses)
(prepn. of, as allergy inhibitor)


RN 148234-91-7 CAPLUS

CN Benzeneacetamide, 4-hydroxy-N-[(4-hydroxy-3-methoxyphenyl)methyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 148235-12-5 CAPLUS

CN Acetamide, N-[(3-hydroxy-4-methoxyphenyl)methyl]-N-[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 148235-22-7 CAPLUS

CN Acetamide, N-[(2-(4-hydroxy-3-methoxyphenyl)ethyl)-N-[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



=> s l3 and vanill?

10 L3

18568 VANILL?

L5 4 L3 AND VANILL?

=> s L5 AND (TUMOR OR CARCINOMA OR SCLEROSIS OR PSORIASIS OR KERATOSIS OR ASTHMA OR RHINITIS OR ATHERO? OR RESTENOSIS)

277459 TUMOR

115452 TUMORS

315962 TUMOR

(TUMOR OR TUMORS)

99854 CARCINOMA

23296 CARCINOMAS

157 CARCINOMATA

106398 CARCINOMA

(CARCINOMA OR CARCINOMAS OR CARCINOMATA)

15689 SCLEROSIS

27 SCLEROSES

15707 SCLEROSIS

(SCLEROSIS OR SCLEROSES)

8799 PSORIASIS

1082 KERATOSIS

286 KERATOSES

1278 KERATOSIS

(KERATOSIS OR KERATOSES)

20778 ASTHMA

20 ASTHMAS

20785 ASTHMA

(ASTHMA OR ASTHMAS)

3497 RHINITIS

41546 ATHERO?

4595 RESTENOSIS

L6 0 L5 AND (TUMOR OR CARCINOMA OR SCLEROSIS OR PSORIASIS OR KERATOSIS
S OR ASTHMA OR RHINITIS OR ATHERO? OR RESTENOSIS)

=> dis hist

(FILE 'HOME' ENTERED AT 14:22:44 ON 16 MAY 2003)

FILE 'REGISTRY' ENTERED AT 14:22:56 ON 16 MAY 2003

L1 STRUCTURE UPLOADED

L2 1 S L1 SSS SAM

L3 11 S L1 SSS FULL



FILE 'CAPLUS' ENTERED AT 14:23:59 ON 16 MAY 2003

L4 1 S L3 AND (TUMOR OR CARCINOMA OR SCLEROSIS OR PSORIASIS OR KERAT

L5 4 S L3 AND VANILL?

L6 0 S L5 AND (TUMOR OR CARCINOMA OR SCLEROSIS OR PSORIASIS OR KERAT

=>



chain nodes :

7 8 9 10 11 12 13 14 15

ring nodes :

1 2 3 4 5 6

chain bonds :

1-13 4-7 6-12 7-8 8-9 8-15 9-11 9-10 12-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-13 6-12 7-8 8-9 8-15 9-11 12-14

exact bonds :



4-7 9-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS



chain nodes :
 7 8 9 10 11 12 13 14 15

ring nodes :
 1 2 3 4 5 6

chain bonds :
 1-13 4-7 6-12 7-8 8-9 8-15 9-11 9-10 12-14

ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :
 1-13 6-12 7-8 8-9 8-15 9-11 12-14

exact bonds :
 4-7 9-10

normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS